Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Motownwingon Dec 20, 2018 11:12am
177 Views
Post# 29140430

Realistic expectations

Realistic expectationsPL dismissal should have been done a long time ago. He is leaving the company with no FDA approval, no partnership, no cash whatsoever and no viable short term options as reflected in the current SP and targets (TD = 0.30$). Remember that PLI confirmed that they need to sell shares at current price just to be able to cover payroll and keep the lights on. Closing over the holiday is a survival measure taken in crisis due to the lack of business activity, lack of revenues and the need to conserve cash. At best, I see a modest opportunity at some point in 2019 if they make progress with the FDA approval and get some modest partnership deal, for an uptick to maybe 0.60$. If they cannot get there due to lack of cash, a takeover at a bargain basement price is another option. Expectation of a homerun with this company should be forgotten. Their focus right now is just to survive. JIMO GLTA
Bullboard Posts